Clinical Trials Logo
  1. Home
  2. Glomerulonephritis, IGA
  3. NCT02232776

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Glomerulonephritis, IGA Clinical Trial

Official title:
A Prospective Study Evaluating the Efficacy and Safety of Losartan in Children With Immunoglobulin A Nephropathy

Clinical Trial Summary

The investigators hypothesize that using Losartan would help decrease proteinuria in controlling proteinuria in children with immunoglobulin A nephropathy.

Clinical Trial Description

Twenty nine patient with IgA nephropathy with proteinuria (urine protein to creatinine ratio > 0.3 mg/mg) were included in the study. All patients had received losartan treatment for 24 weeks. Changes in blood pressure, proteinuria, renal function, and biochemical parameters were prospectively evaluated before and at 4 weeks and 24 weeks. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02232776
Study type Interventional
Source Seoul National University Hospital
Contact
Status Completed
Phase Phase 3
Start date October 2014
Completion date April 2017
View Details
See also
  Status Clinical Trial Phase
Terminated NCT03841448 - A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN) Phase 2
Recruiting NCT04020328 - Leflunomide Plus Low Dose Corticosteroid in Immunoglobulin A (IgA) Nephropathy With Renal Insufficiency Phase 4
Recruiting NCT04092491 - Study of the IgA Repertoire During IgA Deposition Nephropathy.
Not yet recruiting NCT05797051 - Application of Hyperspectral Imaging in the Diagnosis of Glomerular Diseases
Recruiting NCT05791162 - Interest of Follicular Helper Lymphocytes / Regulatory Follicular Helper Lymphocytes Ratio in IgA Nephropathy N/A
Terminated NCT02647255 - Trial of Plasma Exchange for Severe Crescentic IgA Nephropathy Phase 2/Phase 3
Recruiting NCT02160132 - A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes. Phase 2
Recruiting NCT01184599 - A Prospective Study of the Kidney Protective Effect of Aliskiren in Hypertensive Patients With IgA Nephropathy Phase 4
Active, not recruiting NCT00378443 - ACEi/ARB Alone Versus ACEi/ARB Plus Steroids in the Treatment of Primary IgA Nephropathy, a RCT N/A
Completed NCT00396721 - Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy Phase 2
Recruiting NCT01802034 - Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)
Recruiting NCT05510323 - Efficacy of Immunosuppressive Therapy for IgA Nephropathy With Stage 3 or 4 CKD Phase 3
Completed NCT00446251 - Effects of Rituximab and Mycophenolate Mofetil (MMF) on Highly Sensitized Patients Awaiting Renal Transplant Phase 2
Active, not recruiting NCT04663204 - A Study of the Safety and Activity of Sparsentan for the Treatment of Incident Patients With Immunoglobulin A Nephropathy Phase 2
Completed NCT00521508 - Role of Regulatory T Cells in Pathogenesis of Primary IgA Nephropathy N/A
Completed NCT00446459 - Effects of Mycophenolate Mofetil (MMF) On Anti-HLA (Human Leukocyte Antigen)Antibody Levels In Patients Awaiting Cadaveric Renal Transplant. Phase 2